NXC-201
Cell therapy
Also known as HBI0101
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:AL Amyloidosis
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for AL Amyloidosis: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| NXC-201: this drug | Stage not on record | Cell therapy | BCMA (TNFRSF17) | Weak signal | NCT06097832: NEXICART-2 interim (n=45, Sept 2026 8-K): 89% (40/45) IRC-assessed complete response (CR) rate, with 4 additional patients MRD-negative (up to 98% potential CR); 0 relapses observed to date; no ICANS or enterocolitis reported. | |
| Anselamimab (Amlypave) | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Daratumumab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Birtamimab | Discontinued | Monoclonal antibody | Misfolded immunoglobulin light chain (AL amyloid) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent